Sumitomo Pharma Am patents expiration
1. Aptiom patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5753646 | SUMITOMO PHARMA AM | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
Jun, 2021
(2 years ago) | |
| US9206135 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702536 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 4 days from now) | |
| US11364247 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 4 days from now) | |
| US10695354 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 4 days from now) | |
| US10675287 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 4 days from now) | |
| US9643929 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(1 year, 11 months from now) | |
| US9763954 | SUMITOMO PHARMA AM | Therapeutical uses of eslicarbazepine |
Sep, 2028
(4 years from now) | |
| US9566244 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(4 years from now) | |
| US10912781 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(4 years from now) | |
| US8372431 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(5 years from now) | |
| US9750747 | SUMITOMO PHARMA AM | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have bee...
Dosage: TABLET;ORAL
APTIOM family patents
2. Kynmobi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11077068 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(2 years ago) | |
| US9855221 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(2 years ago) | |
| US10888499 | SUMITOMO PHARMA AM | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
Feb, 2022
(2 years ago) | |
| US9931305 | SUMITOMO PHARMA AM | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(2 years ago) | |
| US8663687 | SUMITOMO PHARMA AM | Film compositions for delivery of actives |
Feb, 2023
(1 year, 2 months ago) | |
| US8765167 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(2 months ago) | |
| US8603514 | SUMITOMO PHARMA AM | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(28 days ago) | |
| US10821074 | SUMITOMO PHARMA AM | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
| US10420763 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9669021 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9044475 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9669019 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9283219 | SUMITOMO PHARMA AM | Sublingual films |
Jun, 2030
(6 years from now) | |
| US9326981 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US8846074 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(7 years from now) | |
| US8414922 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(7 years from now) | |
| US11419769 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(7 years from now) | |
| US10449146 | SUMITOMO PHARMA AM | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(11 years from now) | |
| US10959943 | SUMITOMO PHARMA AM | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM;SUBLINGUAL
KYNMOBI family patents
3. Lonhala Magnair Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6962151 | SUMITOMO PHARMA AM | Inhalation nebulizer |
Oct, 2020
(3 years ago) | |
| US7316067 | SUMITOMO PHARMA AM | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step |
Sep, 2022
(1 year, 7 months ago) | |
| US8511581 | SUMITOMO PHARMA AM | Fluid droplet production apparatus and method |
Nov, 2023
(5 months ago) | |
| US7458372 | SUMITOMO PHARMA AM | Inhalation therapy device |
Nov, 2024
(6 months from now) | |
| US7931212 | SUMITOMO PHARMA AM | Fluid droplet production apparatus and method |
Nov, 2025
(1 year, 6 months from now) | |
| US11278683 | SUMITOMO PHARMA AM | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Aug, 2026
(2 years from now) | |
| US9265900 | SUMITOMO PHARMA AM | Disposable ampoule for an aerosol generating device |
Dec, 2028
(4 years from now) | |
| US10940110 | SUMITOMO PHARMA AM | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations |
Feb, 2029
(4 years from now) | |
| US9789270 | SUMITOMO PHARMA AM | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Oct, 2030
(6 years from now) | |
| US9168556 | SUMITOMO PHARMA AM | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer |
Sep, 2032
(8 years from now) | |
| US9604018 | SUMITOMO PHARMA AM | Aerosol therapy device |
May, 2033
(9 years from now) | |
| US10376661 | SUMITOMO PHARMA AM | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element |
Sep, 2035
(11 years from now) | |
| US10688518 | SUMITOMO PHARMA AM | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator |
Nov, 2036
(12 years from now) | |
| US10744277 | SUMITOMO PHARMA AM | Aerosol delivery device and method of operating the aerosol delivery device |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd); A method of using an aerosol delivery device to aerosolize glycopyrrolate for the ...
Dosage: SOLUTION;INHALATION
LONHALA MAGNAIR KIT family patents